Premium
Endocannabinoid system in neurodegenerative disorders
Author(s) -
Basavarajappa Balapal S.,
Shivakumar Madhu,
Joshi Vikram,
Subbanna Shivakumar
Publication year - 2017
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.14098
Subject(s) - endocannabinoid system , neuroscience , cannabinoid receptor , cannabinoid , biology , receptor , antagonist , biochemistry
Most neurodegenerative disorders ( NDD s) are characterized by cognitive impairment and other neurological defects. The definite cause of and pathways underlying the progression of these NDD s are not well‐defined. Several mechanisms have been proposed to contribute to the development of NDD s. These mechanisms may proceed concurrently or successively, and they differ among cell types at different developmental stages in distinct brain regions. The endocannabinoid system, which involves cannabinoid receptors type 1 ( CB 1R) and type 2 ( CB 2R), endogenous cannabinoids and the enzymes that catabolize these compounds, has been shown to contribute to the development of NDD s in several animal models and human studies. In this review, we discuss the functions of the endocannabinoid system in NDD s and converse the therapeutic efficacy of targeting the endocannabinoid system to rescue NDD s.